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a b s t r a c t
Vaccines to methamphetamine (meth) were designed by covalently attaching a meth hapten (METH)
to peptide constructs that contained a conformationally biased, response-selective molecular adjuvant,
YSFKPMPLaR (EP54). Rats immunized with EP54-containing meth vaccines generated serum antibody
titers to authentic meth, an immune outcome that altered meth self-administration. Immunization
increased meth self-administration suggesting pharmacokinetic antagonism. The ability of immune sera
to bind a METH-modiﬁed target protein dramatically decreased during and shortly after the meth selfadministration assay, suggesting effective sequestration of free meth. However, the binding ability of
immune sera to the METH-modiﬁed target protein was recovered 34 days after meth-free clearance time.
© 2009 Elsevier Ltd. All rights reserved.

1. Introduction
The illicit manufacture, distribution, and abuse of methamphetamine (meth) have risen dramatically in the past decade
imposing enormous public health, welfare, and law enforcement
burdens worldwide. Meth represents the fastest growing drug
threat in the United States [1] and is a major problem in the
American Midwest [1–3], a rural region that provides access to
agricultural ammonia, a key ingredient in its illicit synthesis, and a
remote setting that enables makeshift laboratories to operate in a
more clandestine manner. Of particular concern is the strong association between this increase in meth abuse and the transmission
of communicable diseases such as hepatitis A [4].
The scourge of meth abuse and its devastating effects on society and family life underscore the need for an effective method of
inhibiting its addictive, pharmacologic effects. Presently, no direct
intervention method exists, the mainstay of therapy being behavior
modiﬁcation and treatment with antidepressants to help a patient

∗ Corresponding author. Tel.: +1 402 559 5353.
E-mail address: sdsander@unmc.edu (S.D. Sanderson).
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2009.02.105

through withdrawal. A bothersome issue with a highly addictive
drug like meth, however, is the high rate of relapse [5–8]. Thus, a
therapy is urgently needed that is capable of (1) effectively antagonizing the drug in circulation prior to its distribution to the brain
and (2) sustaining this antagonizing effect long enough to minimize
relapse. Such a therapy, when used as a complement to standard
treatments, would provide a powerful combination approach for
treating meth addiction.
An innovative therapeutic approach capable of providing these
latter two attributes is immunization with an appropriately
designed meth vaccine. Vaccination will induce the immune system to generate meth-speciﬁc antibodies (Ab), which will bind
free meth in circulation with high afﬁnity, thus decreasing/altering
meth distribution to the brain. Also, vaccination has the potential of sustaining this anti-meth immune response in the face of
repeated ingestions of meth and for a period of time beyond the
initial cessation of meth use, thus providing protection during that
crucial time frame when the patient is highly susceptible to relapse.
Also, the antagonizing effects of such an immunologic approach
would occur outside the central nervous system (CNS) and would
not interfere with behavior modiﬁcation or CNS-acting medications.
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Vaccines to cocaine [9,10], heroin [11], and nicotine [12–15] have
been used in the active immunization of rats and shown capable of
producing high sera titers of drug-speciﬁc Abs, which attenuated
the psychoactive and locomotor effects of subsequent drug challenges. These vaccines were generated via conventional designs
wherein multiple drug haptens were covalently conjugated to a
carrier protein, which was then admixed with an adjuvant for the
deliverable drug vaccine.
Byrnes-Blake et al. [16] showed appreciable serum titers of
anti-meth Abs in rats immunized with a similarly designed meth
vaccine. Importantly, they showed that neither Ab titer nor Ab
afﬁnity were affected by the concomitant administration of meth
during the course of immunization, suggesting that meth use during a patient’s immunization schedule (a likely scenario) will not
adversely affect the production of anti-meth Abs. Unfortunately,
this anti-meth Ab response was ineffective in attenuating locomotor activities in rats challenged with meth, suggesting that the
vaccine design and/or its administration schedule were not optimized.
In this paper we describe the design of novel, peptide-based,
molecular adjuvant-containing vaccines to meth and their use in
producing short-term and long-term anti-meth outcomes in rats.
The vaccines used in this study were composed of three basic
components, the ﬁrst being the molecular adjuvant, YSFKPMPLaR
(EP54), which is a conformationally biased, response-selective agonist of complement component C5a65–74 . EP54 retains C5a-like
immune stimulatory properties, but with signiﬁcantly reduced
C5a-like inﬂammatory properties [17–20]. The role of the molecular adjuvant EP54 in these vaccines is to target covalently attached
Ags to and activate the Ag processing and presentation capacity of
C5a receptor-bearing antigen presenting cells [21–23], particularly
dendritic cells (DCs) [24].
The second vaccine component is a T-cell epitope from tetanus
toxin TT593–599 (YSYFPSV) [25], which was covalently attached to
the N-terminus of EP54. This epitope was used to engage CD4+
helper T-cells in order to provide the necessary T-cell help for the
Ab-producing B cells during epitope/hapten presentation by DCs
activated by EP54. The third component is a meth hapten (METH)

synthesized to allow the covalent attachment (via amide bond formation) to either the N-termini of the TT epitope-EP54 peptide or
EP54 (monovalent vaccines) or also to the ε-amino group of an
extra Lys residue, which was added to the N-terminal end of the
TT epitope-EP54 peptide or EP54 (divalent vaccines).
In this paper we present the immunologic outcomes of rats vaccinated with these EP54-containing vaccines in terms of initial and
sustained meth-speciﬁc serum Ab titers and their ability to attenuate/alter meth self-administration. These results are discussed
against the backdrop of such an immunologic approach being used
as a routine method of treating meth abuse/addiction.
2. Materials and methods
2.1. Peptide synthesis
Peptides were synthesized by standard solid phase methods on an Aapptec Apex 396 synthesizer using the Fmoc
(9-ﬂuorenylmethoxycarbonyl) method of orthogonal synthesis on a
pre-loaded Fmoc-Arg Wang resin. Peptides were puriﬁed by preparative and analytical HPLC and characterized by conﬁrmation of
molecular mass with MALDI mass spectrometry (see below).
2.2. Hapten (METH) synthesis (Scheme 1)
The METH hapten shown in Scheme 1 was synthesized by a
modiﬁcation of the basic scheme described by Byrnes-Blake et al.
[16]. Conﬁrmation of the chemical modiﬁcations contained in our
homologues, as well as synthetic yields, were consistent with those
reported for the parent hapten [16].
2.2.1. (S)-N-methyl-N-(1-methyl-2-phenylethyl)acetamide (2)
S-(+)methamphetamine (1) (2.23 g, 14.9 mmol) was dissolved
in 100 ml dichloromethane (CH2 Cl2 ) containing ﬁve equivalents
(10.4 ml) of triethylamine (TEA). To this stirred solution was added
18 mmol (1.42 g) of acetyl chloride dropwise over 10 min. This solution was stirred overnight at room temperature and the solvent
removed in vacuo. The residue was dissolved in CH2 Cl2 (75 ml),

Scheme 1.
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washed two times each with 1N HCl, saturated brine, water, and
dried over Mg2 SO4 . The CH2 Cl2 was removed in vacuo to yield S(+)-N-acetylmethamphetamine (2) as a light brown oil. The NMR
spectra indicated a 1:1-mixture of rotamers. 1 H NMR (500 MHz,
CDCl3 ) ı 1.10 (d, J = 6.8 Hz, 1.5 H), 1.26 (d, J = 6.4 Hz, 1.5H), 1.75 (s,
1.5H), 1.98 (s, 1.5H), 2.64–2.82 (m, 2H), 2.78 (s, 1.5H), 2.85 (s, 1.5H),
3.96–4.09 (m, 0.5H), 4.99–5.09 (m, 0.5H), 7.09–7.35 (m, 5H). MF,
C12 H17 NO; MH+ = 192.
2.2.2. (S)-4-[2-(acetylmethylamino)propyl]--oxobenzenebutanoic acid ethyl ester (3)
To a mixture of compound 2 (5.38 g, 28.13 mmol) in CH2 Cl2
(100 ml) at 0 ◦ C was added ethyl succinyl chloride (9.26 g,
56.26 mmol) followed by AlCl3 (17.87 g, 134 mmol) in three portions. The reaction was stirred overnight at room temperature,
cooled to 0 ◦ C, and quenched with 3 M aqueous HCl (100 ml). After
the mixture was diluted with CH2 Cl2 (100 ml), the organic layer
was separated, washed with 3 M aqueous HCl (100 ml) and water
(200 ml), dried over MgSO4 , and concentrated to give a crude
product (14.18 g) that was used in the next step without further
puriﬁcation. The NMR spectra indicated 3:2-mixture of rotamers.
1 H NMR (500 MHz, CDCl ) ı 1.14 (d, J = 6.4 Hz, 1.8H), 1.27 (t, J = 6.9 Hz,
3
3H), 1.28 (d, J = 6.4 Hz, 1.2H), 1.81 (s, 1.2H), 2.02 (s, 1.8H), 2.61–2.92
(m, 4H), 2.80 (s, 1.8H), 2.87 (s, 1.2H), 3.29 (t, J = 6.6 Hz, 2H), 4.01–4.11
(m, 0.4H), 4.16 (q, J = 6.9 Hz, 2H), 5.01–5.11 (m, 0.6H), 7.19–7.36 (m,
2H), 7.85–7.98 (m, 2H).
2.2.3. (S)-4-[2-(acetylmethylamino)propyl]benzenebutanoic acid
ethyl ester (4)
A mixture of compound 3 (14.18 g, crude product from the last
step) and 10 wt% Pd/C (1.40 g) in acetic acid (50 ml) was stirred at
room temperature under H2 atmosphere for 48 h. After the mixture was ﬁltered and rinsed with CH2 Cl2 (200 ml), the ﬁltrate was
diluted with CH2 Cl2 (100 ml), washed with water (200 ml) and
saturated aqueous NaHCO3 (100 ml), dried over MgSO4 , and concentrated to give compound 4 as a brown oil (6.97 g, 81%; the
combined yield for the last two steps). The NMR spectra indicated 1:1-mixture of rotamers. 1 H NMR (500 MHz, CDCl3 ) ı 1.09
(d, J = 6.8 Hz, 1.5H), 1.24 (d, J = 6.8 Hz, 1.5H), 1.25 (t, J = 6.8 Hz, 3H),
1.75 (s, 1.5H), 1.88–1.96 (m, 2H), 1.99 (s, 1.5H), 2.30 (t, J = 7.6 Hz, 2H),
2.56–2.81 (m, 4H), 2.78 (s, 1.5H), 2.84 (s, 1.5H), 3.95–4.06 (m, 0.5H),
4.09–4.19 (m, 2H), 4.95–5.06 (m, 0.5H), 6.98–7.15 (m, 4H).
2.2.4. (S)-4-[2-(methylamino)propyl]benzenebutanoic acid
hydrochloride (5) (METH).
A mixture of compound 4 (6.97 g, 22.8 mmol) and 6 M aqueous
HCl (120 ml) was reﬂuxed for 72 h. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was
puriﬁed by crystallization from ether followed by crystallization
from acetonitrile to give the desired compound 5 as a colorless
solid (2.10 g, 34%) mp 130–132 ◦ C. 1 H NMR (500 MHz, DMSO–d6 )
ı 1.08 (d, J = 6.3 Hz, 3H), 1.71–1.82 (m, 2H), 2.19 (t, J = 7.1 Hz, 2H),
2.51–2.64 (m, 6H), 3.08–3.18 (m, 1H), 3.25–3.34 (m, 1H), 7.15 (s,
4H), 9.04 (brs, 2H), 12.05 (s, 1H); 13 C NMR (125.7 MHz, DMSO–d6 ) ı
15.15, 26.40, 29.71, 33.24, 34.15, 38.05, 55.44, 128.71, 129.40, 134.25,
140.20, 174.40.
2.3. Vaccine synthesis
Monovalent (METH-YSFKPMPLaR and METH-YSYFPSVYSFKPMPLaR) and divalent (METH-K(METH)YSFKPMPLaR and METHK(METH)YSYFPSVYSFKPMPLaR) vaccines were generated by coupling METH (5) to the N-terminal and ε-amino moieties of
these peptides while attached to the solid phase resin [15]. The
corresponding free amino groups were generated by selective
deprotection of Fmoc groups and amide bond formation with METH
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was achieved by reaction with the HBTU (2-(1H-benzotriazol-1-yl)1,1,3,3-tetramethyluronium hexaﬂuorophosphate)-activated ester
of METH. The course of this coupling reaction was monitored by
the loss of the free amine on the peptide with ninhydrin. The
peptide-based vaccines were cleaved from the resin and side-chain
protecting groups removed by stirring the resin for 1.5 h at room
temperature in a cleavage cocktail made of TFA (92.5%), water (5%),
and triisopropylsilane (2.5%). To this solution was added an excess
(ca. 100 ml) of cold ether to precipitate the peptide, which was
then collected by centrifugation. Peptides were puriﬁed by analytical and preparative reverse-phase HPLC on C18-bonded silica
columns with a running buffer of 0.1% TFA (Solvent A) and 60%
acetonitrile in 0.1% TFA (Solvent B) as the eluant. Peptides were
characterized by conﬁrmation of molecular mass using MALDI mass
spectrometry.
2.4. Vaccination
Rats were randomly assigned to either the Vaccine or Control
group. The Vaccine group received two injections of 250 g of
vaccine dissolved at 1 mg/ml in sterile water. One injection was subcutaneous (SC) and the other was intraperitoneal (IP). The Control
group received the same number and volume of vehicle injections.
This vaccination procedure was repeated once every 7 days for 5
weeks and serum was collected at weeks 1, 3, and 6. The ﬁnal
vaccination occurred on the last day of Preliminary Training (see
below).
2.5. Determination of Abs to methamphetamine
Prior to immunization of meth administered rats a group was
tested to determine vaccine efﬁcacy. Brieﬂy, 4 rats were immunized with vaccine as described above and bled via retro orbital
puncture. A direct ELISA was used to determine circulating antibody titers to meth. Serum was diluted 2-fold and multiple dilutions
were averaged to determine concentration from the rat IgG standard curve. Using METH-modiﬁed BSA (bovine serum albumin),
ELISA plates (Immulon IV, Dynatech, Chantilly, VA) were coated
at 2 g/well in the presence of bicarbonate buffer, pH 9.6 and
incubated at 37◦ overnight. Plates were washed, blocked using
2% casein for 30 min and rat serum incubated on the plate for
1 h at room temperature. The plates were then washed and
horse raddish peroxidase (HRP) rabbit anti-rat IgG (H&L) antibody added (Sigma Chemical, Co., St. Louis, MO), incubated for
30 min, and developed using TMB substrate. Absorbance was
detected at 450 nm using an MRX II Microplate Reader (Dynatech, Chantilly, VA), data analyzed using Revelations Software from
Dynatech, and expressed in ng/ml using rat IgG as a standard
curve.
2.6. Competitive ELISA
In order to determine the speciﬁcity of the Abs raised against
meth, a competitive ELISA was used as previously described [15].
ELISA plates were coated with METH-modiﬁed BSA as described
above and incubated overnight. In a separate radioimmuno-assay
(RIA) plate, the meth inhibitor and serum were diluted for overnight
incubation at 4 ◦ C. Meth was diluted 2-fold down the plate at a starting concentration of 2000 pmol/well. Serum from immunized rats
was added to the plate at a concentration that would produce a 1.0
O.D. after 30 min of incubation. Following an overnight incubation,
the plate was washed, blocked in 2% casein, and the RIA plate contents transferred over. After 1 h incubation at room temperature,
the plate was washed and an HRP rabbit anti-rat IgG (H&L) (from
above) was added for 30 min. The plate absorbance was detected
as previously described above. Calculation of the competitive ELISA
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was determined using the following formula:
inhibition (%) =

(OD max -BKG) − (OD sample-BKG)
× 100
(OD max -BKG)

2.7. T-cell proliferation assays
To determine proliferative responses of T-cells, PBS (control) or
METH-modiﬁed BSA were added to 96-well ﬂat bottom plates at
a concentration of 50 g/ml. T-cells from immunized and sham
immunized (vehicle control) rats were added at a concentration of
(1 × 105 cells/well) and incubated for 48 h at 37 ◦ C in 5% CO2 , pulsed
with 1.0 Ci/well of [3 H] thymidine (GE Healthcare, Piscataway, NJ)
for 16 h, and harvested on a 96-well harvester (Tomtec, Orange,
CO). Filter paper containing the incorporated thymidine was placed
in scintillation ﬂuid and counted on a 1450 Microbeta Scintillation Counter (Perkin Elmer Life Sciences, Waltham, MA). Data was
expressed as stimulation index (SI) using the following formula:
SI =

(mean cpm/ min of target − BKG)
(mean cpm/ml of control − BKG)

2.8. Self-administration apparatus
Eight standard self-administration chambers (Med-Associates,
Georgia, VT, USA) were used each housed in a PVC soundattenuating cubicle ﬁtted with an exhaust fan and a house light.
Each chamber (30.5 cm × 24.1 cm × 21 cm; l × w × h) had side walls
made of aluminum; the ceiling and front and back walls were clear
polycarbonate. In the bottom center of one aluminum wall was a
recessed dipper receptacle (5.2 cm × 5.2 cm × 3.8 cm; l × w × d). The
dipper arm, when raised, allowed access to 0.1 ml of 26% sucrose
solution (w/v). Retractable levers were located on either side of the
dipper receptacle. To operate the lever required 147 nN of force.
Two white cue lights (28 V, 100 mA) were centered 7 cm above each
lever, 14.6 cm above the metal rod ﬂoor and 3.5 cm from the closest
polycarbonate wall. Each chamber contained a balanced metal arm
with a spring leash attached to a swivel. Tygon® tubing AAQ04103
(VWR, West Chester, PA, USA) extended through the leash and was
connected to a 5 ml syringe mounted on an infusion pump (Med
Associates, PMH-100VS) located outside of the PVC cubicle.
2.9. Meth self-administration methods
2.9.1. Subjects
Ten male Wistar rats weighing 150–175 g upon arrival from
Charles River Laboratories, Inc. (Wilmington, MA, USA) were
housed individually in clear polycarbonate tubs lined with wood
shavings. Water was continuously available in the home cage and
access to chow was restricted during Preliminary Training and
Self-Administration. All sessions were conducted during the light
portion of a 12 h light/dark cycle. Experimental protocols were
approved by the University of Nebraska-Lincoln and University of
Nebraska Medical Center Institutional Animal Care and Use Committee and followed the “Guide for the Care and Use of Laboratory
Animals” (National Research Council, 1996).
2.9.2. Drug
d-Methamphetamine hydrochloride (meth) was purchased
from Sigma (St. Louis, MO, USA), dissolved in 0.9% sterile saline
(w/v), and administered intravenously (IV) at a volume of 36 l per
infusion.

0.1333 (ca. 3 deliveries per min). Two days of lever press autoshaping following dipper training. On a given session only one of the
retractable levers (right or left) was inserted into the chamber for
15 s using a variable time 60 s schedule. If a lever press occurred
before 15 s, the lever was retracted and sucrose was immediately
available for 4 s. If no lever press occurred after 15 s, the lever was
retracted and 4 s access to sucrose was provided. Order of lever presentation (left or right on day 1) was counterbalanced as much as
allowed by sample size. There were 60 presentations of the lever
per session; thus, session length varied somewhat between rats
depending upon when consistent lever pressing developed in the
session. After the last autoshaping session, rats were allowed free
access to rat chow until the end of the surgical recovery period.
2.11. Catheter surgery
Surgery was performed 24 h after the last vaccination and proceeded as described in detail elsewhere [26,27]. Brieﬂy, rats were
anesthetized with 1 ml/kg ketamine hydrochloride (100 mg/ml, IP)
followed by 0.6 ml/kg xylazine hydrochloride (20 mg/ml, IP) (Midwestern Veterinary Supply, Des Moines, IA, USA). One end of a
silastic catheter (CamCaths© IVSA28, Ely, Cambridgeshire, UK) was
implanted into the left external jugular vein. The other end of the
catheter went subcutaneous around the shoulder and was attached
to a metal cannula embedded in a plastic bolt that exited below the
scapula permitting access to the catheter. To manage post-surgical
pain, buprenorphine hydrochloride (0.1 mg/kg; Sigma) was injected
SC immediately following surgery. For that evening and the following day buprenorphine (0.5 mg/kg) was available in the drinking
water. The catheter was ﬂushed twice a day with 0.2 ml of sterile heparinized saline (30 U/ml; Midwest Veterinary Supply). The
ﬁrst ﬁve post-surgical ﬂushes also included 0.1 ml of streptokinase
(ca. 8000 U/ml; Sigma) dissolved in heparinized saline. Catheter
patency of the 10 rats was conﬁrmed with a 0.05 ml IV infusion
of xylazine (20 mg/ml) at the end of the study. This concentration
produces motor ataxia within 5 s if the catheter is patent.
2.12. Self-administration
Five days after surgery (7 days after the last vaccination) rats
started the self-administration phase. Sessions were 60 min and
the house light remained on throughout each session. Which lever
(right or left) functioned as the active (drug) lever was counterbalanced as permitted by sample size. The initial schedule of
reinforcement was a ﬁxed ratio (FR) 1. Thus, each active lever press
produced a 1 s infusion of 0.05 mg/kg meth and simultaneous illumination of the cue light above the active lever. Both levers were
retracted and remained retracted for 1 min following completion
of the FR1. Inactive lever presses were recorded but had no programmed consequence. Rats remained on an FR1 for 5 days. This
schedule was increased to an FR3 (5 days), followed by an FR5 (5
days), an FR10 (3 days), and ﬁnally a progressive ratio (1 day). Increments in the progressive ratio (PR) schedule within session used the
formula 5 × EXP (0.2 × infusion number)–5 [28,29]. Similar to those
studies, we replaced the ﬁrst six values (1, 2, 4, 6, 9, and 12) with 3,
6, and 10, and then continued with the progression provided by the
equation. The resulting sequence of required responses per infusion was: 3, 6, 10, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 179, etc.
[Note: For the blood sample section the ﬁrst blood collection was
approximately 24 h after the PR schedule. The second sample was
taken 34 days later].

2.10. Preliminary training
2.13. Dependent measures and data analysis
Rats were fed 20 g of chow per day during this phase. Dipper
training consisted of a 50 min automated session in which the probability of receiving 4 s access to sucrose in any 4 s interval was

For each FR schedule, the number of methamphetamine infusions was analyzed with a 2-way mixed analysis of variance
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Table 1
EP54 containing vaccines to methamphetamine.
Vaccine 1

METH-YSFKPMPLaR

Vaccine 2

METH-YSYFPSVYSFKPMPLaR

Vaccine 3

Vaccine 4

(ANOVA) with Group (Vaccine or Control) as the between-subjects
factor and Session as the within-subjects factor. To determine
when discrimination between the active and inactive lever was
acquired, the ratio of active to total lever presses was calculated
and then compared to a hypothetical mean of 0.5. Acquisition of the
discrimination was declared when two consecutive session were
signiﬁcantly above 0.5 (i.e., more than half the total responding
on the active lever). For the PR schedule, the last PR completed
(i.e., breakpoint) for each group was compared with an unpaired ttest. Statistical signiﬁcance for all analyses was set at P < 0.05 with
a two-tailed rejection region.
3. Results
Four molecular adjuvant (EP54)-containing vaccines were used
in this study and are shown in Table 1. They consisted of two
monovalent vaccines (Vaccines 1 and 2) and two divalent vaccines
(Vaccines 3 and 4). Fig. 1 shows increased serum Ab reactivity at
week 6 to the METH hapten for Vaccine 2 (1716 ng/ml ± 211) and
Vaccine 4 (858 ng/ml ± 91) P ≤ 0.001 compared to serum from rats
sham immunized with vehicle only (40 ng/ml ± 15). Relative to the
other EP54-containing vaccines, Vaccine 2 appeared to generate the
highest serum Ab titers to METH (P ≤ 0.001) and, therefore, was
chosen for use in subsequent experiments.
The speciﬁcity of these anti-METH Abs generated by Vaccine 2
to methamphetamine was determined using a binding inhibition
assay to the METH hapten in the presence of authentic methamphetamine. Fig. 2 indicates an 80% inhibition of the METH-positive
rat serum in the presence of free methamphetamine, demonstrating Ab speciﬁcity to the drug.

Fig. 1. Ab activity to methamphetamine in male Wistar rats immunized with:
vehicle control (PBS); METH-YSFKPMPLaR (Vaccine 1); METH-YSYFPSVYSFKPMPLaR
(Vaccine 2); METH-K(METH)YSFKPMPLaR (Vaccine 3); and METH-K(METH)YSYFPSVYSFKPMPLaR (Vaccine 4) at weeks 1, 3 and 6. Serum from rats was screened using
METH-modiﬁed BSA as the antigen and extrapolated using rat IgG as a standard
curve. Each bar represents the mean ± S.E. of 4 rats. *P ≤ 0.001, signiﬁcantly different
from the vehicle control. # P ≤ 0.001 signiﬁcantly different form all other vaccines.

Fig. 2. An example of Ab speciﬁcity to meth from rats vaccinated with Vaccine 2.
Sera were incubated in the presence of authentic meth as an inhibitor and then
allowed to bind the METH-modiﬁed BSA antigen. Data are expressed as % inhibition
of immune sera. Data are representative of 4 rats.

Vaccines 2 and 4 incorporated the T-cell epitope YSYFPSV from
tetanus toxin (TT593–599 ) as a component for generating CD4+ T-cell
help in the production of anti-METH/meth Abs [25]. To determine the involvement of this T-cell help, T-cells from spleens of
METH/meth-positive rats immunized with Vaccines 2 and 4 were
isolated and incubated with BSA modiﬁed with METH or a vehicle
control. Fig. 3 shows an increased stimulation index (6.8 ± 0.87) for
Vaccine 2 and (3.5 ± 1.1) for Vaccine 4 when METH-modiﬁed BSA
was used as the antigen relative to vehicle control (1.9 ± 0.19), supporting the involvement of T-cell help in the production of Abs to
meth. These data further indicate that Vaccine 2 would serve as the
best candidate vaccine for use in self-administration studies.
To determine the ability of these anti-METH/meth Abs to reduce
meth distribution to the brain, rats were immunized with Vaccine 2 and then monitored for changes in meth self-administration
relative to sham-vaccinated controls. Fig. 4 shows the number of
infusions earned per session across each FR schedule. The ANOVA
on the infusions earned across the initial FR1 schedule indicated a
main effect of Group, F (1, 8) = 7.10, P = 0.029; the main effect of Session and the Group × Session interaction were not signiﬁcant, F’s < 1.
This analysis indicates that the Vaccine group took more meth than

Fig. 3. T-cell proliferation assay from male Wistar rats immunized with a vehicle
control, Vaccine 2, and Vaccine 3. T-cells were isolated from the spleen, incubated
with a control or METH-modiﬁed BSA meth for 48 h, and pulsed with [3 H]-thymidine
overnight. Data are expressed as a stimulation index of 3 rats. *P = 0.002 signiﬁcantly
different from the vehicle control.
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4. Discussion

Fig. 4. Self-administration of meth following immunization with Vaccine 2. Data
are expressed as the mean number of meth infusions taken per session across each
ﬁxed ratio (FR) schedule of reinforcement for rats in the Vaccine and Control groups.

the Control group during this initial phase of self-administration. As
meth self-administration progressed and the reinforcement schedule increased, this difference was no longer detected: FR3 (F’s ≤ 1.7,
p’s ≥ 0.226), FR5 (F’s ≤ 1.25, p’s ≥ 0.308), FR10 (F’s < 1). Both groups
acquired the discrimination between the active and inactive lever
(data not shown). However, onset of the discrimination was faster
for the Vaccine group than the Control group. The Vaccine group
had signiﬁcantly more than half of their subjects responding on
the active lever by Sessions 4 and 5 of the FR1, whereas the Control group did not meet the criterion until Sessions 3 and 4 of the
FR3. Breakpoints on the PR schedule were highly variable and did
not differ between the Vaccine (70 ± 34.5) and Control (47 ± 18.1)
group, t < 1.
Following the meth self-administration studies, the animals
were checked for serum Ab titers to meth. As shown in Fig. 5 only
background levels of Ab to the meth was observed shortly after
self-administration (186 ± 17). However, following a 34-day clearance of meth, serum Ab titers rebounded to the previous levels
(1664 ± 543) of Ab seen with the original immunizations of Vaccine 2. These data indicate that the anti-meth Abs were bound
by free, circulating meth during self-administration and, consequently, were masked from our binding assays.

Fig. 5. Immune serum activity to METH-modiﬁed BSA 1 week after selfadministration of meth in male Wistar rats immunized with a vehicle control or
Vaccine 2. Data represent the mean ± S.E. of 5–6 rats. *P ≤ 0.001 as compared to the
vehicle control or the vaccinated rats after 1 day of meth self-administration.

The results of this study indicate that immunization with a
peptide-based, molecular adjuvant (EP54)-containing vaccine to
meth (Vaccine 2) can generate meth-speciﬁc Abs in the sera of
rats capable of altering meth self-administration. In contrast to the
immunoconjugate vaccines to meth [16] and other addictive drugs
[8–14] made by the covalent conjugation of numerous drug haptens
to a carrier protein admixed with adjuvant, it is noteworthy that
these anti-meth responses were generated by a vaccine that carried
only one METH hapten and were produced by immunization in the
absence of added adjuvant – the vaccine dissolved merely in PBS.
Development of vaccines from other laboratories has demonstrated similar Ab titers to the one described in this article. However,
the majority of haptenated vaccines to nicotine, cocaine, and meth
were all coupled to KLH (keyhole limpet hemocyanin) or some other
large carrier protein and immunized with oil based adjuvants such
as Ribi or Freunds [14,16,30,31]. Such drug hapten–protein conjugate vaccines to nicotine and cocaine have been taken into phases
I and II trails with some success [12,32]. This present study and
our previous nicotine vaccine study [15] are the ﬁrst to use a novel
peptide-based vaccine in the absence of large carrier proteins and
the use of added adjuvants. The principal experimental approach
for attenuating the effects of meth overdose/abuse is the use of
anti-meth monoclonal Abs (MAbs) that are ﬁrst generated in mice
[33,34]. These MAbs are then infused into rats and then tested using
self-administration studies [35,36]. The EP54-containing vaccines
described in this study offer clear potential advantages over the
use MAbs and protein-conjugate vaccines in that active immunization as often as is need is possible to invoke a sustained, protective
immune response to attenuate the psychoactive effects of meth
with little/no inﬂammatory side-effects from added adjuvants.
The immunologic results presented in this study are consistent
with those observed with an EP54-containing vaccine to nicotine
[15] and with a mechanism we proposed earlier to describe the
molecular adjuvant properties of EP54 (YSFKPMPLaR) and its ability to induce Ag-speciﬁc Ab and cell-mediated immune responses
[20–24]. Brieﬂy, EP54 selectively interacts with C5aRs on antigen presenting cells (especially DCs) and induces the release of
Th1 cytokines. The C5aR/ligand complex then internalizes, which
carries the covalently attached Ag/epitope into intracellular Ag processing pathways. Here, the Ag/epitope is processed and associates
with HLA/MHC determinants for expression on the DC surface.
Thus, EP54 delivers both the Ag and stimulatory signals to C5aRbearing DCs.
Vaccine 2 was designed to exploit the assistance of a promiscuous T-cell epitope (YSYFPSV) derived from tetanus toxin (TT593–599 ).
YSYFPSV is processed by DCs, presented in the context of MHC/HLA
class II, and invokes CD4+ T-cell help to B cells for the production of Abs [25]. Thus, we reasoned that METH-YSYFPSV likewise
would be processed and presented by DCs, particularly when targeted to and activated by EP54. Our expectation was that the
presented YSYFPSV moiety would induce the necessary CD4+ help
for the appropriate B cell(s) to recognize the attached METH hapten, which together would drive the hapten-speciﬁc Ab response.
This involvement of the TT593–599 epitope appears substantiated
by the anti-METH/meth immune outcomes generated by Vaccines
2 and 4 and the relative lack of response with Vaccines 1 and 3,
which lacked this epitope. This epitope involvement in the antimeth immune outcome is further substantiated by the increased
stimulation index observed from T-cells obtained from the spleens
of rats immunized with Vaccine 2.
The use of TT593–599 in these EP54-containing vaccines is attractive because it is well-characterized immunologically, is small and
easy to synthesize, and has been used in other larger, peptidebased vaccines to invoke CD4+ T-cell help for B cells to generate

M.J. Duryee et al. / Vaccine 27 (2009) 2981–2988

Ag-speciﬁc Abs [25]. Also, it is possible that this CD4+ response in
humans may be readily invoked with such TT/molecular adjuvantcontaining vaccines to meth since most people already have been
immunized to tetanus.
Given the ability of Vaccine 2 to induce meth-speciﬁc Abs in
serum, the efﬁcacy of this immune outcome to reduce the psychoactive effects of meth was evaluated in meth self-administration
in rats. There was a signiﬁcant but transient effect of Vaccine
2 on meth self-administration. Surprisingly, vaccinated rats displayed an increase rather than a decrease in drug intake relative
to controls only in the initial FR1 phase of self-administration. This
pattern of results is consistent with the view that meth-speciﬁc
Abs are sequestering meth in peripheral circulation, thus decreasing, at least early on, the ability of some of the meth from entering
the central nervous system; i.e., meth-speciﬁc Abs are essentially
functioning as a pharmacokinetic antagonist [13]. Vaccinated rats
presumably compensated for this pharmacokinetic antagonism by
increasing drug intake. Indeed, such compensation is seen in selfadministration experiments when pharmacological antagonists are
used [28,37,38].
Following the self-administration studies, animals were tested
for the presence of meth-speciﬁc Abs. These assays showed barely
discernable levels of Abs, which were lower than unimmunized
control animals. When these animals were allowed to recovery
from meth self-administration and the sera were re-tested, antimeth Ab levels returned to previous levels. This suggests that the
Abs bound free meth with high afﬁnity/avidity in vivo, minimizing
meth access to the brain and the need for animals to compensate by
increasing self-administration. Thus, vaccinated animals behaved
essentially like controls in the later phases of self-administration.
It appeared that animals would take in more meth to compensate
for the effects of the vaccine; however, later when all the Abs were
saturated with meth, they were equal to the controls.
These data suggest that this vaccine could be useful in absorbing
some of the meth in peripheral circulation early in meth exposure.
However, our ﬁndings suggest that compensation may occur resulting in overall increased meth administration. This ﬁnding implies
that such a vaccination approach would be most effectively used
in association with standard behavior modiﬁcation and the use
of other medications as a complementary approach to stop meth
use and addiction. Some authors have suggested that vaccination
could be used as a prevention strategy for at-risk individuals [13,38],
whereas others have expressed some skepticism and urged extreme
caution if such an approach is routinely adopted [26,39,40]. At least
with vaccination as a preventative against meth abuse, our ﬁndings
that vaccinated rats increase early meth intake suggests the latter
perspective may be more appropriate. It will be of interest in future
research to determine if similar compensation occurs in an animal
model that simulates a relapse opportunity in a meth addict that
has been abstinent for some time (i.e., as an intervention approach).
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